Amol Akhade, Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:
“Zanidatamab, Her2 bispecific, got accelerated approval by the US FDA for advanced BTC with IHC 3 plus for second line.
Based upon 52 % of ORR and DOR of 14.9 months in phase 2 trial.
Will it stand in phase 3 trial? Let’s hope so.”
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors.
He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
